CELC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CELC is a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. My view is positive because the stock has strong technical support from a bullish trend, major clinical trial success, and broad analyst upgrades with higher price targets. The lack of short-term trading signals means this is not a momentum-only setup, but the long-term thesis is strengthened by the recent Phase 3 breakthrough and the Street’s increasing confidence. For an impatient buyer, this is still an acceptable entry now rather than waiting for a perfect pullback.
The technical trend is constructive. MACD histogram is positive at 1.294, though slightly contracting, which suggests the rally is still intact but may be cooling modestly. RSI_6 near 51 is neutral, so the stock is not overbought. The moving averages are bullish with SMA_5 > SMA_20 > SMA_200, a strong trend confirmation. Price at 131.31 is above the pivot of 128.853 and below resistance at 145.829, leaving room for further upside. The short-term pattern data shows some near-term weakness risk, but the broader trend remains bullish.
The biggest catalyst is the positive Phase 3 VIKTORIA-1 result, where gedatolisib met its primary endpoint with statistically significant and clinically meaningful progression-free survival improvement. This drove a wave of analyst upgrades and higher price targets. The company also appears to have a potentially important upcoming ASCO late-breaker presentation, which could reinforce the story and support further re-rating.
A director plans to sell 25,000 shares worth about $3.52 million, which is a modest negative signal. The company is still unprofitable, with negative net income and EPS in the latest quarter. Also, stock trend modeling suggests some short-term pullback risk over the next week to month despite the strong longer-term setup.
In 2025/Q4, Celcuity reported no revenue, so this is still a development-stage company rather than a commercial growth story. Net income remained negative at -50.97 million, though losses improved 39.07% year over year. EPS was -0.97, also improved 14.12% YoY. The latest quarter shows progress on the loss side, but the key investment case is still clinical and pipeline-driven rather than financial operating strength.
Wall Street sentiment is strongly positive and improving. Recent actions include multiple price target raises: Craig-Hallum to $189, Needham to $157, Guggenheim to $165, Stifel to $150, and Citizens to $160, with several reiterating Buy or Outperform ratings. H.C. Wainwright upgraded the stock to Buy from Neutral and set a $165 target. The pros view is that the Phase 3 data materially de-risks the pipeline and expands commercial potential. The main con view is that the company is still pre-revenue and valuation now depends heavily on execution and regulatory progress.
